New Zealand - English - Medsafe (Medicines Safety Authority)

te arai biofarma limited - dimethyl fumarate 240mg - modified release capsule - 240 mg - active: dimethyl fumarate 240mg excipient: colloidal silicon dioxide crospovidone sheffcoat clear asa 5x00294 sheffcoat white ent tec 5x00273 capsugel green op. c162 magnesium stearate microcrystalline cellulose povidone - indicated in patients with relapsing multiple sclerosis to reduce the frequency of relapses and to delay the progression of disability.

New Zealand - English - Medsafe (Medicines Safety Authority)

te arai biofarma limited - budesonide 3mg - modified release capsule - 3 mg - active: budesonide 3mg excipient: gelatin   ethylcellulose dispersion type b ink black 10a2 iron oxide black iron oxide red methacrylic acid copolymer polysorbate 80 purified talc sugar spheres titanium dioxide   triethyl citrate - indicated for the induction of remission in patients with mild to moderate crohn's disease affecting the ileum and/or the ascending colon.

New Zealand - English - Medsafe (Medicines Safety Authority)

te arai biofarma limited - lacosamide 10 mg/ml;   - oral solution - 10 mg/ml - active: lacosamide 10 mg/ml   excipient: acesulfame potassium aspartame carmellose sodium citric acid glycerol macrogol 4000 propylene glycol purified water sodium chloride sodium methyl hydroxybenzoate sorbitol strawberry flavour 10810007 - lacosamide te arai is indicated as: - monotherapy in the treatment of partial seizures with or without secondary generalisation in patients with epilepsy aged 16 years and older. - add-on therapy in the treatment of partial seizures with or without secondary generalisation in patients with epilepsy aged 4 years and older. - add-on therapy in the treatment of primary generalised tonic-clonic seizures in patients with idiopathic generalised epilepsy aged 4 years and older.